Data shows majority of Australian sites are open for clinical trial activity

9th April 2020 (Last Updated April 22nd, 2020 11:43)

Sponsored by Novotech Sponsored by Visit Company
Data shows majority of Australian sites are open for clinical trial activity
Clinicians in Australia are hard at work.

Novotech, the Asia-Pacific CRO, has published data detailing the current status of clinical trials in the Asia-Pacific region during the global COVID-19 crisis.

According to their data, the top 10 biotech sites in Australia are still open for clinical trial activity – with many sites modifying their practices to ensure continuity of operations. These 10 sites account for about a third of the clinical activity of biotechnology companies in the country. All top 10 sites are currently open for clinical trial activity including monitoring.

Novotech’s Bulletin research series taps local knowledge of fundamentals in the sector and shows which countries in the region are able to support clinical research for biotechnology companies during this time.

While the situation is always evolving, Australia appears to be managing the crisis well. Sites have changed how they manage trials in line with the most recent health guidelines from both the WHO and the Australian government – and most are still able to deliver the clinical trial services their clients need.

Because Australia is well placed to deliver clinical assessment, it’s also believed that study delays caused by COVID-19 could possibly be addressed by activating new sites in Australia and Asia.

“Australia now has one of the highest testing rates in the world with more than 11,600 people tested for every million.”

The reason for this thinking is Australia’s attractive start-up times, world leading investigators and research teams..

Australia now has one of the highest testing rates in the world with more than 11,600 people tested for every million according to Worldometer, a statistics website whose purpose is to make statistics widely available for free

A majority of sites continue to be very interested in new studies. Patient recruitment is temporarily on hold in many public sites while recruitment continues in private sites (particularly phase 1 units).

At the moment, over 60% of Novotech sites in Australia allow for remote monitoring and 30% of the sites remain open to on-site monitoring.

View and Download the COVID-19 Australia Data Bulletin here.

Free Whitepaper

The Trends and Future Trajectory of Biotech Clinical Trials

The COVID-19 pandemic has changed the landscape of clinical trials with innumerable vaccines and therapies racing through trials for market or emergency use approval. Looking forward, these changes are projected to accelerate further with innovation shifting from big pharma to biotechs, leading to a greater need for R&D outsourcing.

Data analyst and business intelligence firm GlobalData has partnered with Novotech, the Asia-Pacific CRO, to compile a white paper that explores some of the trends seen in the past year and outline forecasts for what’s next in the industry. With Asia-Pacific expected to have 24% of the global CRO market by 2024, this white paper also explains why the regions is ideal for outsourcing clinical R&D and how drug development plans help biotechs.